TSX News -
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, announced […]